➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Harvard Business School
McKinsey
Baxter

Last Updated: January 17, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AKB-6548

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for AKB-6548?

AKB-6548 is an investigational drug.

There have been 35 clinical trials for AKB-6548. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2017.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Aerpio Therapeutics, and Mitsubishi Tanabe Pharma Corporation.

There are fourteen US patents protecting this investigational drug and one hundred and thirty-two international patents.

Recent Clinical Trials for AKB-6548
TitleSponsorPhase
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)Akebia Therapeutics Inc.Phase 2
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)The University of Texas Health Science Center, HoustonPhase 2
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypotension or Open Angle GlaucomaAerpio TherapeuticsPhase 2

See all AKB-6548 clinical trials

Clinical Trial Summary for AKB-6548

Top disease conditions for AKB-6548
Top clinical trial sponsors for AKB-6548

See all AKB-6548 clinical trials

US Patents for AKB-6548

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AKB-6548   Start Trial Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Akebia Therapeutics, Inc. (Cambridge, MA)   Start Trial
AKB-6548   Start Trial Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Akebia Therapeutics, Inc. (Cambridge, MA)   Start Trial
AKB-6548   Start Trial Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Akebia Therapeutics, Inc. (Cambridge, MA)   Start Trial
AKB-6548   Start Trial Prolyl hydroxylase inhibitors and methods of use Warner Chilcott Company, LLC (Pajardo, PR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AKB-6548

Drugname Country Document Number Estimated Expiration Related US Patent
AKB-6548 Argentina AR099354 2033-11-15   Start Trial
AKB-6548 Australia AU2014348523 2033-11-15   Start Trial
AKB-6548 Australia AU2019202144 2033-11-15   Start Trial
AKB-6548 Brazil BR112016011065 2033-11-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Harvard Business School
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.